COMMUNIQUÉS West-GlobeNewswire

Mereo BioPharma Group plc Announces Positive Early 6 Month Data from the Open Label Arm of the Phase 2b Clinical Study in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with the Anti-Sclerostin Antibody, BPS-804 (setrusumab)
30/05/2019
Clear and encouraging percentage changes over baseline in trabecular volumetric bone mineral density measured at the radius at an early readout Expect topline 12 month data from the blinded arms of study to be available [...]
Novartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthma
30/05/2019
Low dose QMF149 ( indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to inhaled corticosteroid ( [...]
BrainStorm Announces Second Clinical Site to Enroll Patients in Its Progressive MS Phase 2 Study
30/05/2019
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today [...]
Mesoblast Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for remestemcel-L in the Treatment of Acute Graft Versus Host Disease
30/05/2019
MELBOURNE, Australia and NEW YORK, May 29, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that it has filed the first [...]
Helix BioPharma Corp. Closes Private Placement
30/05/2019
RICHMOND HILL, Ontario, May 29, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment [...]
Indus Holdings, Inc. Reports Record Revenue in the First Quarter 2019 Financial Results
30/05/2019
Indus reports revenue of $6.4 million, representing 180% revenue growth year over year SALINAS, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Indus Holdings, Inc. ("Indus") (CSE:INDS), a leading, vertically integrated [...]
Eve & Co Announces Second German Supply Agreement; Provides Update on First German Supply Agreement
29/05/2019
TORONTO, May 29, 2019 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSXV: EVE; OTCQB: EEVVF) is pleased to announce that its wholly-owned subsidiary Natural MedCo Ltd. has entered into [...]
GILEAD AND GALAPAGOS TO PRESENT LATEST DATA ON FILGOTINIB AT THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR 2019)
29/05/2019
-- Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions -- Foster City, Calif. and Mechelen, Belgium; May 29, 2019; 22.30 CET - Gilead [...]
electroCore Announces Comprehensive Redeployment and Cost Reduction Plan
29/05/2019
Management to host conference call and webcast at 8:30am ET on Thursday, May 30 BASKING RIDGE, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, [...]
Aptose Announces Proposed Public Offering of Common Shares
29/05/2019
SAN DIEGO and TORONTO, May 29, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its Common [...]
Xenon Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
29/05/2019
BURNABY, British Columbia, May 29, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer [...]
Myovant Sciences Announces $100 Million Public Offering of Common Shares
29/05/2019
BRISBANE, Calif. and BASEL, Switzerland, May 29, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“ Myovant ”), a clinical-stage healthcare company focused on developing and commercializing innovative therapies [...]
Supernus to Present at the Jefferies 2019 Global Healthcare Conference
29/05/2019
ROCKVILLE, Md., May 29, 2019 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Kane Biotech to Showcase Technologies and Products at the 2019 BIO International Convention
29/05/2019
WINNIPEG, Manitoba, May 29, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of [...]
Amicus Therapeutics Announces Public Offering of Common Stock
29/05/2019
CRANBURY, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced a $150 million underwritten public offering of its common stock. J.P. Morgan Securities LLC, Goldman [...]
BioDelivery Sciences Announces Upcoming Investor Conference Presentations
29/05/2019
RALEIGH, N.C., May 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic [...]
Synthorx to Present at Jefferies 2019 Healthcare Conference
29/05/2019
SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for [...]
Bellicum Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
29/05/2019
HOUSTON, May 29, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) , a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
Guardant Health to Present at the William Blair 2019 Growth Stock Conference
29/05/2019
REDWOOD CITY, Calif., May 29, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast [...]

Pages